Products
Pre-made Inotuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-275
Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-275-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-275-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-275-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-275-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
| INN Name | Inotuzumab |
| Target | CD22 |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2005 |
| Companies | Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group |
| Conditions Approved | Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Active | Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia |
| Conditions Discontinued | Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma |
| Development Tech | na |
<